Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Healthcare diagnostics momentum backed by Q2 record revenue of $622.7M, adjusted EBITDA of $99.7M, ARR up to $105.5M from $53.5M YoY, raised 2026 Imaging Center guidance, reaffirmed Digital Health guidance, and multiple FDA 510(k) clearances.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Rising Debt ⢠Weak Liquidity ⢠Thin Profitability RDNT's quarterly recovery and positive cash flow are outweighed by rising leverage, weaker liquidity, thin profitability, and demanding valuation, warranting caution.
Price Behavior
Key Price Behavior Insights: ⢠Momentum weakening ⢠Support holding ⢠Lower highs Support Level: $72.39 Resistance Level: $75.70; $76.80â$77.30 RDNT has turned mildly bearish below $75.70 after peaking near $77.31, with $72.39 support critical and a reclaim of $75.70 then $76.80â$77.30 needed to revive upside.
Sentiment & News
Key News Insights: ⢠Record revenue ⢠Raised guidance ⢠Digital acceleration RadNet's record Q2 results, raised Imaging Center guidance, and accelerating Digital Health growth reinforce a positive growth outlook despite lower adjusted EPS.
AI Summary
RDNT's investment case hinges on DeepHealth and advanced-imaging growth converting record revenue and EBITDA into sustained free cash flow, expanding margins, and lower leverage; at ~25x EV/EBITDA, investors should wait for clearer digital profitability and earnings conversion before underwriting further upside.
Description
RadNet, Inc. operates a network of outpatient diagnostic imaging centers across multiple U.S. states, providing services such as MRI, CT, PET, mammography and other multimodality imaging procedures. The company also supplies imaging IT systems, including picture archiving and communication solutions, and has developed software tools to support radiologist interpretation in areas including mammography, lung and prostate cancer. Founded in 1981 and headquartered in Los Angeles, RadNet owned and managed 347 centers as of December 31, 2021.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 10 | Aug 17 | RDNT | RadNet, Inc. | Healthcare diagnostics momentum backed by Q2 record revenue of $622.7M, adjusted EBITDA of $99.7M, ARR up to $105.5M from $53.5M YoY, raised 2026 Imaging Center guidance, reaffirmed Digital Health guidance, and multiple FDA 510(k) clearances. | Closed | -1.8% |
| Sep 8 | Sep 15 | RDNT | RadNet, Inc. | RadNet shows strong Q2 operational momentum with record revenue and EBITDA growth, raised full-year guidance, expanding reimbursement streams, and technical momentum with a ~36% surge over 21 trading days; near-term price upside possible above resistance at ~$73, despite high leverage and valuation risks. | Closed | +4.2% |